Thymosin beta-4 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-11. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
=== Treatment === Consumption of the death cap is a medical emergency requiring hospitalization. The four main categories of therapy for poisoning are preliminary medical care, supportive measures, specific treatments, and liver transplantation. Preliminary care consists of gastric decontamination with either activated carbon or gastric lavage; due to the delay between ingestion and the first symptoms of poisoning, it is common for patients to arrive for treatment many hours after ingestion, potentially reducing the efficacy of these interventions. Supportive measures are directed towards treating the dehydration which results from fluid loss during the gastrointestinal phase of intoxication and correction of metabolic acidosis, hypoglycemia, electrolyte imbalances, and impaired coagulation. No definitive antidote is available, but some specific treatments have been shown to improve survivability. High-dose continuous intravenous penicillin G has been reported to be of benefit, though the exact mechanism is unknown, and trials with cephalosporins show promise. Some evidence indicates intravenous silibinin, an extract from the blessed milk thistle (Silybum marianum), may be beneficial in reducing the effects of death cap poisoning. A long-term clinical trial of intravenous silibinin began in the US in 2010. Silibinin prevents the uptake of amatoxins by liver cells, thereby protecting undamaged liver tissue; it also stimulates DNA-dependent RNA polymerases, leading to an increase in RNA synthesis.
=== ENSO Costero === Coined by the Peruvian Comité Multisectorial Encargado del Estudio Nacional del Fenómeno El Niño (ENFEN), ENSO Costero, or ENSO Oriental, is the name given to the phenomenon where the sea-surface temperature anomalies are mostly focused on the South American coastline, especially from Peru and Ecuador. Studies point many factors that can lead to its occurrence, sometimes accompanying, or being accompanied, by a larger EP ENSO occurrence, or even displaying opposite conditions from the observed ones in the other Niño regions when accompanied by Modoki variations. ENSO Costero events usually present more localized effects, with warm phases leading to increased rainfall over the coast of Ecuador, northern Peru and the Amazon rainforest, and increased temperatures over the northern Chilean coast, and cold phases leading to droughts on the Peruvian coast, and increased rainfall and decreased temperatures on its mountainous and jungle regions. Because they don't influence the global climate as much as the other types, these events present lesser and weaker correlations to other significant ENSO features, neither always being triggered by Kelvin waves, nor always being accompanied by proportional Southern Oscillation responses. According to the Coastal Niño Index (ICEN), strong El Niño Costero events include 1957, 1982–83, 1997–98 and 2015–16, and La Niña Costera ones include 1950, 1954–56, 1962, 1964, 1966, 1967–68, 1970–71, 1975–76 and 2013.
This involves electron capture or positron decay of potassium-40 to argon-40. Potassium-40 has a half-life of 1.3 billion years, so this method is applicable to the oldest rocks. Radioactive potassium-40 is common in micas, feldspars, and hornblendes, though the closure temperature is fairly low in these materials, about 350 °C (mica) to 500 °C (hornblende).
Sources: en.wikipedia.org
== History == In 1628, English physician William Harvey discovered that blood circulates around the body. Soon thereafter, the first blood transfusion was attempted. In 1665 another English doctor Richard Lower successfully used blood transfusion between dogs to keep them alive. Karl Landsteiner is recognized as the father of transfusion medicine. Landsteiner is credited with the first classification of human blood into the four types (A, B, AB, O) of the ABO blood group system.
This alpha-ketoglutarate-dependent hydroxylase requires α-ketoglutaric acid, which is converted to succinic acid as a by-product. Aromadendrin is a precursor to many other derivatives. In some citrus fruits, naringenin is converted to prunin, the precursor to naringin, a compound which is responsible for the bitter taste of grapefruit.
== Cytokine therapy == Cytokines are proteins produced by many types of cells present within a tumor. They can modulate immune responses. The tumor often employs them to allow it to grow and reduce the immune response. These immune-modulating effects allow them to be used as drugs to provoke an immune response. Two commonly used cytokines are interferons and interleukins. Interleukin-2 and interferon-α are cytokines, proteins that regulate and coordinate the behavior of the immune system. They have the ability to enhance anti-tumor activity and thus can be used as passive cancer treatments. Interferon-α is used in the treatment of hairy-cell leukaemia, AIDS-related Kaposi's sarcoma, follicular lymphoma, chronic myeloid leukaemia and melanoma. Interleukin-2 is used in the treatment of melanoma and renal cell carcinoma.
Cryofixation is a technique for fixation or stabilisation of biological materials as the first step in specimen preparation for the electron microscopy and cryo-electron microscopy. Typical specimens for cryofixation include small samples of plant or animal tissue, cell suspensions of microorganisms or cultured cells, suspensions of viruses or virus capsids and samples of purified macromolecules, especially proteins. Types of cryo-fixation are freezing-drying, freezing-substitution and freezing-etching.
Sources: en.wikipedia.org
===== Mechanism of a single selectin binding ===== A single PSGL-1 and selectin binding is similar to conventional protein binding when the force is kept constant, with a dissociation constant. As the force exerted starts to increase, the dissociation constant decreases, causing binding to become stronger. As the force reach a threshold level of 11 pN, the dissociation constant starts to increase again, weakening the bond, causing the bond to exhibit a slip bond property.
== Companies == Contaminated products found in the China AQSIS tests include baby formula products produced by the following companies, in order of highest concentration found. Shijiazhuang Sanlu Group, Shanghai Panda Dairy, Qingdao Shengyuan Dairy, Shanxi Gu Cheng Dairy, Jiangxi Guangming Yingxiong Dairy, Baoji Huimin Dairy, Inner Mongolia Mengniu Dairy, Torador Dairy Industry (Tianjin), Guangdong Yashili Group, Hunan Peiyi Dairy, Heilongjiang Qilin Dairy, Shanxi Yashili Dairy, Shenzhen Jinbishi Milk, Scient (Guangzhou) Infant Nutrition, Guangzhou Jinding Dairy Products Factory, Inner Mongolia Yili Industrial Group, Yantai Ausmeadow Nutriment, Qingdao Suncare Nutritional Technology, Xi'an Baiyue Dairy, Yantai Leilei Dairy, Shanghai Baoanli Dairy, and Fuding Chenguan Dairy.
==== Semisynthesis ==== The semisynthesis of steroids often begins from precursors such as cholesterol, phytosterols, or sapogenins. The efforts of Syntex, a company involved in the Mexican barbasco trade, used Dioscorea mexicana to produce the sapogenin diosgenin in the early days of the synthetic steroid pharmaceutical industry.
Following the nationwide collapse of the Whig Party in 1854, many of Knoxville's Whigs, including Brownlow, were unwilling to support the new Republican Party formed by northern Whigs, and instead aligned themselves with the anti-immigrant American Party (commonly called the "Know Nothings"). When this movement disintegrated, Knoxville's ex-Whigs turned to the Opposition Party. In 1858, Opposition Party candidate Horace Maynard, with Brownlow's endorsement, soundly defeated Democratic candidate J.C. Ramsey (J.G.M. Ramsey's son) for the 2nd district's congressional seat.
Internal medicine is the medical specialty dealing with the prevention, diagnosis, and treatment of adult diseases. According to some sources, an emphasis on internal structures is implied. In North America, specialists in internal medicine are commonly called "internists". Elsewhere, especially in Commonwealth nations, such specialists are often called physicians. These terms, internist or physician (in the narrow sense, common outside North America), generally exclude practitioners of gynecology and obstetrics, pathology, psychiatry, and especially surgery and its subspecialities. Because their patients are often seriously ill or require complex investigations, internists do much of their work in hospitals. Formerly, many internists were not subspecialized; such general physicians would see any complex nonsurgical problem; this style of practice has become much less common. In modern urban practice, most internists are subspecialists: that is, they generally limit their medical practice to problems of one organ system or to one particular area of medical knowledge. For example, gastroenterologists and nephrologists specialize respectively in diseases of the gut and the kidneys. In the Commonwealth of Nations and some other countries, specialist pediatricians and geriatricians are also described as specialist physicians (or internists) who have subspecialized by age of patient rather than by organ system. Elsewhere, especially in North America, general pediatrics is often a form of primary care. There are many subspecialities (or subdisciplines) of internal medicine:
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.